Abstract
Although resistance to tigecycline has been reported in surveillance studies, very few reports have described the emergence of resistance in vivo. We report two cases of patients with infections due to SHV-12-producing Klebsiella pneumoniae and K. pneumoniae carbapenemase-3 (KPC-3)-producing Escherichia coli, which developed tigecycline resistance in vivo after treatment. The reported limited experience underlines the risk of occurrence of a tigecycline MIC increase under treatment pressure.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Anti-Bacterial Agents / therapeutic use
-
Bacterial Proteins / biosynthesis
-
Bacterial Proteins / metabolism
-
Drug Resistance, Multiple, Bacterial
-
Escherichia coli / drug effects*
-
Escherichia coli / enzymology
-
Escherichia coli Infections / drug therapy*
-
Escherichia coli Infections / microbiology
-
Humans
-
Klebsiella Infections / drug therapy*
-
Klebsiella Infections / microbiology
-
Klebsiella pneumoniae / drug effects*
-
Klebsiella pneumoniae / enzymology
-
Male
-
Microbial Sensitivity Tests
-
Middle Aged
-
Minocycline / analogs & derivatives*
-
Minocycline / pharmacology
-
Minocycline / therapeutic use
-
Tigecycline
-
beta-Lactamases / biosynthesis
-
beta-Lactamases / metabolism
Substances
-
Anti-Bacterial Agents
-
Bacterial Proteins
-
Tigecycline
-
beta-lactamase SHV-12
-
beta-Lactamases
-
beta-lactamase KPC-3, Klebsiella pneumoniae
-
carbapenemase
-
Minocycline